IRRAS AB publishes Interim Report for the period, January to September 2021
Fifth Consecutive Quarter of Revenue Growth “Q3 marked our company’s 5th consecutive quarter of growth, even with increased impact during the quarter from the COVID-19 Delta variant. This growth and the strengthening foundation of our business show that IRRAS is well positioned to continue this positive growth trajectory.” “We are pleased with our accomplishments during the third quarter of 2021, and our continued progress across the key elements of our business – revenue growth, operational efficiency, and clinical data generation – confirms our forward momentum.” Will Martin,